

UTILITY
PATENT APPLICATION
TRANSMITTAL

Attorney Docket No.

ORT-1414

First Inventor

QIN, Ning

Title

CDNA ENCODING THE HUMAN ALPHA2 DELTA4
CALCIUM CHANNEL SUBUNIT

Express Mail Label No.

EL710607409US

(only for new nonprovisional applications under 37 CFR
1.53(b))

APPLICATION ELEMENTS

See MPEP Chapter 600 concerning utility patent application
contents.

ADDRESS TO:

Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(submit an original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.
3. ☒ Specification [Total Pages 107]
(Preferred arrangement set forth below)
- Descriptive Title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a
computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☒ Drawing(s) (35 USC 113) [Total Sheets 3]
5. Oath or Declaration [Total Pages 3]
- a. ☒ Unexecuted (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
- i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or
Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence
Submission (if applicable, all necessary)

- a. ☒ Computer Readable Form (CRF)
- b. ☒ Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☒ paper
- c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement
(IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Request and Certifications under 35 U.S.C. 122
(b)(2)(B)(i). Applicant must attach form
PTO/SB/35 or its equivalent.
17. ☐ Other

18. ☐ If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a
preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-Part (CIP) of prior application No.: , filed

Prior application information: Examiner Group Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an
oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying
continuation or divisional application and is hereby incorporated by reference. The incorporation can only be
relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 000027777 or ☐ Correspondence Address below

Name: Philip S. Johnson, Esq.

Address: Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003 USA

20. TELEPHONE CONTACT

Please direct all telephone calls or telefaxes to Myra H. McCormack at:

Telephone: (732) 524-6814 Fax: (732) 524-2808


21. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME

Myra H. McCormack

Reg. No. 36,602

SIGNATURE



DATE

April 11, 2001

FEE TRANSMITTAL	<i>Complete if Known</i>	
	Application Number	
	Filing Date	April 11, 2001
	First Named Inventor	QIN, Ning
	Group Art Unit	
	Examiner Name	
	Attorney Docket Number	ORT-1414


FEE CALCULATION

CLAIMS AS FILED

(1)	(2)	(3)	(4)	(5)
FOR:	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE \$710.00
TOTAL CLAIMS	22 - 20 =	2	x 18.00	\$ 36.00
INDEPENDENT CLAIMS	8 - 3 =	5	x 80.00	\$ 400.00
MULTIPLE DEPENDENT CLAIMS	<input type="checkbox"/>	N/A	\$270.00	
			TOTAL FEES	\$1,146.00

METHOD OF PAYMENT

- ☒ Please charge Deposit Account No. 10-0750/ORT-1414/MHM in the amount of \$1,146.00. Three copies of this sheet are enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/ORT-1414/MHM. Three copies of this sheet are enclosed.

SUBMITTED BY:		<i>Complete (if applicable)</i>
Typed or Printed Name	Myra H. McCormack	Reg. No. 36,602
Signature		Date: April 11, 2001
		Deposit Account No. 10-0750



DOCKET NO. ORT-1414

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: QIN, et al.

For : CDNA ENCODING THE HUMAN NOVEL ALPHA2 DELTA4 CALCIUM
CHANNEL SUBUNIT

Express Mail Certificate

"Express Mail" mailing number: EL710607409US

Date of Deposit: April 11, 2001

I hereby certify that this complete application, including specification pages, claims, drawings, unexecuted Declaration and Power of Attorney, sequence disk, and sequence listing, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Debra A. Wojcik

(Typed or printed name of person mailing paper or fee)


(Signature of person mailing paper or fee)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: QIN et al.
For: cDNA ENCODING THE HUMAN ALPHA2 DELTA4 CALCIUM
CHANNEL SUBUNIT
Filed: April 11, 2001
Serial No: TBD

VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I hereby verify that the computer readable diskette enclosed herewith includes the same information as provided in the Sequence Listing of the subject application, and that this statement is made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.


Myra H. McCormack
Reg. No. 36,602

DATE: April 11, 2001